Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

What Is the Long-Term Outcome of Lesions Deferred Using FFR/iFR?

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxelThe presence of inducible ischemia is an essential prerequisite to obtain clinical benefits from revascularization through angioplasty. In that sense, the measurement of fractional flow reserve (FFR) is the gold standard as regards invasive methods assessing the functional significance of epicardial artery stenosis.

As opposed to FFR, the measurement of the instantaneous wave-free ratio (iFR) does not require hyperemia, which means that each of these indices may represent a different aspect of artery physiopathology.


Read also: The Use of Intravascular Imaging to Guide PCI Reduces Cardiovascular Death Risk, Compared to Angiography”.


Two recently published large studies (DEFINE-FLAIR and iFR SWEDEHEART) measured and compared both indices, but they did not assess the clinical outcomes of lesions with discordant results in the two tests. In consequence, we lacked information enough to support the conclusion that both methods are equivalent.

From the 3V FFR-FRIENDS (3-Vessel Fractional Flow Reserve for the Assessment of Total Stenosis Burden and Its Clinical Impact in Patients With Coronary Artery Disease) study, 821 deferred lesions in 374 patients assessed with both methods were included in this study.

The primary endpoint was a composite of death, infarction, and ischemia-driven revascularization at 2 years.


Read also: Critical Lower Limb Ischemia Should Be Taken into Account in TAVR”.


Lesions were classified according to FFR and iFR cutpoints into concordant normal (group 1: FFR >0.80 and iFR >0.89), high FFR and low iFR (group 2: FFR >0.80 and iFR ≤0.89), low FFR and high iFR (group 3: FFR ≤0.80 and iFR >0.89), and, finally, concordant abnormal (group 4: FFR ≤0.8 and iFR ≤0.89).

Deferred lesions despite FFR ≤0.80 and iFR ≤0.89 (group 4, concordant abnormal) showed significantly higher rates of 2-year events, compared with concordant normal lesions (7.2% in low FFR vs. 2.4% in high FFR; p < 0.001, and 8.1% in low iFR vs. 2.4% in high iFR; p < 0.001). Both indices were able to predict events as a continuous variable.

The discriminant ability for both indices was comparable (c-index 0.677 vs. 0.685; p = 0.857).


Read also: Peripheral Vascular Disease Is Associated to More Events in TAVR”.


Among all described groups classified according to FFR and iFR levels, only group 4 (concordant abnormal) showed a significantly higher number of events, compared with group 1, concordant normal (hazard ratio [HR]: 7.708; 95% confidence interval [CI]: 2.621 to 22.667; p < 0.001).

Conclusion

Both FFR and iFR were capable of predicting future events. Events increased only when both measurements resulted in an abnormal value. Discordant results between FFR and iFR were not associated with an increase in events.

Editorial

This is an extremely interesting study that seeds doubt on how to proceed with discordant lesions. Additionally, it might force us to perform both measurements for all lesions, which is highly unpractical. A reasonable course of action seems to be an initial assessment through iFR, which is faster and does not require adenosine hyperemia (thus saving time, money, and uncomfortable symptoms for the patient). If the result falls in a grey area such as ±0.03 from the cutpoint (between 0.86 and 0.92 iFR), use the adenosine and, under hyperemia, measure FFR and make an FFR-based decision. After all, this last method is the gold standard.

Another interesting piece of information that derives from this study is continuous event prediction, which means that FFR = 0.81 is not the same as FFR = 0.98 (although both values are considered normal in the classification). A patient with FFR = 0.81 is undoubtedly at higher risk than another with FFR = 0.98. In such cases, clinical criteria holds an undisputable importance that cannot be dimmed by a magic number resulting from a measurement.

Original title: Clinical Outcomes According to Fractional Flow Reserve or Instantaneous Wave-Free Ratio in Deferred Lesions.

Reference: Joo Myung Lee et al. J Am Coll Cardiol Intv 2017, article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...